Regen Biopharma INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OID
Regen Biopharma, Inc. filed its annual 10-K, revealing a significant increase in net loss to $1.27 million and substantial doubt about its ability to continue as a going concern, despite reduced operating cash burn.
OID
Regen Biopharma's 10-K filing reveals continued focus on regenerative medicine applications, with ongoing research and development efforts and reliance on related party transactions for revenue and financing.